Evidence map›Paper›PMID 41675896›Full record

ArticleAnnals of medicine and surgery (2012)2026

Effect of triple versus dual antiplatelet therapy in patients undergoing percutaneous intervention: systematic review and meta-analysis with GRADE system.

Islam Mohsen Elhaddad, Hesham Elsayed, Reem Sayad, Rana Abdelnasser Abdelrahman, Noran Magdy Shalma, Mohamed K Harfoush, Shimaa Essam El-Din Hmd, Rahmah Sameh Shaheen, Afag Abdullah Algunaid Babeker, Ahmed Saad Elsaeidy

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Islam Mohsen ElhaddadDamietta Faculty of Medicine, Al-Azhar University, Damietta, Egypt.ORCID https://orcid.org/0009-0007-4969-2764
Hesham ElsayedFaculty of Medicine, Tanta University, Tanta, Egypt.ORCID https://orcid.org/0009-0003-4004-9132
Reem SayadHistology Department, Faculty of Medicine, Assiut University, Assiut, Egypt.ORCID https://orcid.org/0000-0002-4378-2714
Rana Abdelnasser AbdelrahmanFaculty of Medicine, Benha University, Benha, Egypt.
Noran Magdy ShalmaFaculty of Medicine, Tanta University, Tanta, Egypt.ORCID https://orcid.org/0000-0001-9231-7213
Mohamed K HarfoushFaculty of Medicine, Alexandria University, Alexandria, Egypt.ORCID https://orcid.org/0000-0002-5033-7918
Shimaa Essam El-Din HmdFaculty of Medicine, Assiut University, Assiut, Egypt.ORCID https://orcid.org/0009-0007-6274-2607
Rahmah Sameh ShaheenFaculty of Medicine, Benha University, Benha, Egypt.ORCID https://orcid.org/0000-0001-5200-6138
Afag Abdullah Algunaid BabekerFaculty of Medicine, The National Ribat University, Khartoum, Sudan.ORCID https://orcid.org/0009-0007-7429-4995
Ahmed Saad ElsaeidyFaculty of Medicine, Benha University, Benha, Egypt.ORCID https://orcid.org/0000-0002-1643-9750

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: To lower major adverse cardiac events following percutaneous coronary intervention (PCI), antiplatelet therapy should be continued. We evaluated triple antiplatelet therapy (TAT) versus standard dual treatment (DAT) in patients having percutaneous intervention for coronary artery disease. Methods: On 17 July 2023, we systematically searched PubMed, Scopus, and the Web of Science databases. This systematic review included studies that assessed the effect of TAT versus DAT after PCI. The level of evidence of the included trials was assessed using the Grading of Recommendations, Assessment, Development, and Evaluation approach. Results: Twenty-seven studies were included in this systematic review and meta-analysis. The meta-analysis showed that TAT is associated with a significant reduction in major adverse cardiac events (MACEs) at 9- and 12-month follow-up periods (risk ratio [RR] = 0.39, 95% confidence interval [CI], 0.20-0.77; Conclusion: TAT appears to be more effective than DAT in reducing MACEs, TLR, and TVR in acute coronary syndrome patients after PCI. TAT is almost as safe as DAT in these patients because there is a statistically insignificant difference in most of the adverse effects between these two groups.

Indexed as

Acute coronary syndromeBleeding outcomesCoronary artery diseaseDual antiplatelet therapyMajor adverse cardiac eventsPercutaneous coronary interventionSystematic review and meta-analysisTarget lesion revascularizationTarget vessel revascularizationTriple antiplatelet therapy

Identifiers

PMID41675896
PMCPMC12889486

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.